Fusion Pharma Stock Is Trading Higher As FDA Clears Early-Stage Study For Radiopharmaceutical In Neck, Bladder Cancers

by Vandana Singh, Benzinga Editor

July 29, 2021 7:09 AM | 1 min read |

The FDA has signed off Fusion Pharmaceuticals Inc's FUSN Investigational New Drug (IND) applications for [225Ac]-FPI-1966 (FPI-1966) and imaging agent [111In]-FPI-1967 (FPI-1967).
FPI-1966 is a targeted alpha therapy (TAT) designed to use vofatamab, a human monoclonal antibody, to target and deliver actinium-225 to tumor sites expressing fibroblast growth factor 3 (FGFR3), a protein overexpressed in multiple tumor types.
The planned Phase 1 trial will investigate safety, tolerability, and pharmacokinetics and establish the recommended Phase 2 dose.
Price Action: FUSN shares are up 10.2% at $9.05 during the premarket session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar

Posted In: Biotech News Health Care Small Cap FDA General bladder cancer Briefs Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.